New Insights into MASLD and Potential Treatment Targets
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing global health concern. Recent research led by Lund University in Sweden has identified altered gene expression patterns linked to liver fibrosis in MASLD, offering a potential new target for drug development and improved disease management. This discovery could pave the way for treatments to unhurried or even reverse liver damage in the early stages of this increasingly prevalent condition.
Understanding MASLD
MASLD affects approximately 30% of adults worldwide and is closely associated with obesity, type 2 diabetes and other metabolic disorders [1]. While it can remain asymptomatic for years, MASLD can progress to more serious liver conditions, including liver fibrosis, cirrhosis, and liver failure [2]. Liver fibrosis, characterized by the build-up of scar tissue, is a key indicator of disease progression and a critical prognostic marker [2].
The Lund University Study
The study, published in the scientific journal eLife, analyzed liver samples from individuals undergoing bariatric surgery in Australia. Researchers compared samples from 76 participants with early-stage MASLD to those from 33 individuals without the disease [2]. Gene expression profiling and metabolite analysis revealed altered expression of specific genes associated with GTP-binding proteins in individuals with both MASLD and fibrosis, but not in those with MASLD alone. This suggests these gene expression shifts are specifically linked to scarring development.
Targeting Fibrosis: A Potential New Treatment Approach
Further experiments using GTPase inhibitors on human cells showed a reduction in collagen secretion, a central feature of fibrosis [2]. This finding supports the idea that targeting this pathway could prevent or reduce fibrosis in MASLD. According to Dr. Philipp Kaldis, professor of metabolic disorders and liver disease at Lund University Diabetes Centre, “If researchers develop a drug that inhibits the gene expression from being altered – and this would reduce the formation of liver fibrosis – then this could be a novel treatment option” [2].
Prevalence and Risk Factors
A recent study analyzing data from over 27,000 Swedish adults aged 50-64 found that 18.1% had MASLD [3]. Prevalence was higher in men (25.5%) than in women (11.2%). The risk of MASLD increased with the presence of cardiometabolic risk factors, with those having obesity, hypertension, and type 2 diabetes exhibiting the highest risk (70.2%) [3]. Among those with MASLD, nearly 25% were at risk of advanced fibrosis [3].
Looking Ahead
While further research is needed to confirm causality and develop safe and effective therapies, this study provides a promising new target for treating MASLD. The collaborative effort between Lund University and researchers in Australia, Singapore, and Sweden highlights the importance of international cooperation in tackling this global health challenge. Early detection and lifestyle interventions remain crucial for managing MASLD, but the prospect of targeted drug therapies offers hope for improved outcomes for those at risk of developing advanced liver disease.